nodes	percent_of_prediction	percent_of_DWPC	metapath
Amoxapine—HTR3A—vagus nerve—esophageal cancer	0.0492	0.205	CbGeAlD
Amoxapine—HTR7—vagus nerve—esophageal cancer	0.0318	0.133	CbGeAlD
Amoxapine—HTR2A—vagus nerve—esophageal cancer	0.0198	0.0829	CbGeAlD
Amoxapine—Paresthesia of limbs—Methotrexate—esophageal cancer	0.0116	0.0529	CcSEcCtD
Amoxapine—Atrial arrhythmia—Capecitabine—esophageal cancer	0.0107	0.049	CcSEcCtD
Amoxapine—Arrhythmia supraventricular—Capecitabine—esophageal cancer	0.00768	0.0351	CcSEcCtD
Amoxapine—HTR7—neck—esophageal cancer	0.00698	0.0292	CbGeAlD
Amoxapine—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.00695	0.0318	CcSEcCtD
Amoxapine—Ileus paralytic—Capecitabine—esophageal cancer	0.00689	0.0315	CcSEcCtD
Amoxapine—HTR3A—digestive system—esophageal cancer	0.00558	0.0233	CbGeAlD
Amoxapine—HTR2B—smooth muscle tissue—esophageal cancer	0.00534	0.0223	CbGeAlD
Amoxapine—CHRM1—trachea—esophageal cancer	0.00493	0.0206	CbGeAlD
Amoxapine—HTR7—epithelium—esophageal cancer	0.00475	0.0198	CbGeAlD
Amoxapine—HTR3A—lung—esophageal cancer	0.00466	0.0195	CbGeAlD
Amoxapine—ADRA1A—epithelium—esophageal cancer	0.00458	0.0191	CbGeAlD
Amoxapine—HTR7—smooth muscle tissue—esophageal cancer	0.00457	0.0191	CbGeAlD
Amoxapine—HTR2A—neck—esophageal cancer	0.00435	0.0182	CbGeAlD
Amoxapine—SLC6A4—digestive system—esophageal cancer	0.00426	0.0178	CbGeAlD
Amoxapine—HTR2B—digestive system—esophageal cancer	0.00422	0.0176	CbGeAlD
Amoxapine—HTR7—trachea—esophageal cancer	0.0042	0.0175	CbGeAlD
Amoxapine—ORM1—lung—esophageal cancer	0.00417	0.0174	CbGeAlD
Amoxapine—Body temperature increased—Carboplatin—esophageal cancer	0.00388	0.0178	CcSEcCtD
Amoxapine—SLC6A3—lung—esophageal cancer	0.00388	0.0162	CbGeAlD
Amoxapine—Tingling sensation—Capecitabine—esophageal cancer	0.0037	0.0169	CcSEcCtD
Amoxapine—Petechiae—Capecitabine—esophageal cancer	0.00362	0.0165	CcSEcCtD
Amoxapine—HTR7—digestive system—esophageal cancer	0.00361	0.0151	CbGeAlD
Amoxapine—SLC6A4—lung—esophageal cancer	0.00355	0.0149	CbGeAlD
Amoxapine—HRH1—epithelium—esophageal cancer	0.00354	0.0148	CbGeAlD
Amoxapine—CHRM1—lung—esophageal cancer	0.00354	0.0148	CbGeAlD
Amoxapine—HTR2B—lung—esophageal cancer	0.00352	0.0147	CbGeAlD
Amoxapine—ADRA2A—bronchus—esophageal cancer	0.00343	0.0143	CbGeAlD
Amoxapine—HRH1—smooth muscle tissue—esophageal cancer	0.00342	0.0143	CbGeAlD
Amoxapine—Lacrimation increased—Capecitabine—esophageal cancer	0.00323	0.0148	CcSEcCtD
Amoxapine—Nasal congestion—Cisplatin—esophageal cancer	0.00322	0.0147	CcSEcCtD
Amoxapine—HRH1—trachea—esophageal cancer	0.00313	0.0131	CbGeAlD
Amoxapine—SLC6A2—lung—esophageal cancer	0.00313	0.0131	CbGeAlD
Amoxapine—ADRA2A—trachea—esophageal cancer	0.00308	0.0129	CbGeAlD
Amoxapine—Coordination abnormal—Capecitabine—esophageal cancer	0.00303	0.0139	CcSEcCtD
Amoxapine—HTR7—lung—esophageal cancer	0.00302	0.0126	CbGeAlD
Amoxapine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00299	0.0137	CcSEcCtD
Amoxapine—HTR2A—epithelium—esophageal cancer	0.00296	0.0124	CbGeAlD
Amoxapine—ORM1—lymph node—esophageal cancer	0.00285	0.0119	CbGeAlD
Amoxapine—HTR2A—smooth muscle tissue—esophageal cancer	0.00285	0.0119	CbGeAlD
Amoxapine—DRD2—lung—esophageal cancer	0.00285	0.0119	CbGeAlD
Amoxapine—HRH1—digestive system—esophageal cancer	0.0027	0.0113	CbGeAlD
Amoxapine—Petechiae—Methotrexate—esophageal cancer	0.00269	0.0123	CcSEcCtD
Amoxapine—Desloratadine—ABCB1—esophageal cancer	0.00268	0.286	CrCbGaD
Amoxapine—HTR2A—trachea—esophageal cancer	0.00262	0.0109	CbGeAlD
Amoxapine—Mental disability—Capecitabine—esophageal cancer	0.00258	0.0118	CcSEcCtD
Amoxapine—Pancreatitis—Cisplatin—esophageal cancer	0.00249	0.0114	CcSEcCtD
Amoxapine—Vascular purpura—Capecitabine—esophageal cancer	0.00242	0.011	CcSEcCtD
Amoxapine—HTR2B—lymph node—esophageal cancer	0.00241	0.0101	CbGeAlD
Amoxapine—Libido decreased—Capecitabine—esophageal cancer	0.00233	0.0107	CcSEcCtD
Amoxapine—Increased appetite—Capecitabine—esophageal cancer	0.0023	0.0105	CcSEcCtD
Amoxapine—Atrial fibrillation—Capecitabine—esophageal cancer	0.00228	0.0104	CcSEcCtD
Amoxapine—Vasculitis—Methotrexate—esophageal cancer	0.00227	0.0104	CcSEcCtD
Amoxapine—HTR2A—digestive system—esophageal cancer	0.00225	0.00941	CbGeAlD
Amoxapine—HRH1—lung—esophageal cancer	0.00225	0.00941	CbGeAlD
Amoxapine—Purpura—Capecitabine—esophageal cancer	0.00224	0.0103	CcSEcCtD
Amoxapine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00223	0.0102	CcSEcCtD
Amoxapine—Myocardial infarction—Cisplatin—esophageal cancer	0.00222	0.0101	CcSEcCtD
Amoxapine—ADRA2A—lung—esophageal cancer	0.00221	0.00924	CbGeAlD
Amoxapine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00221	0.0101	CcSEcCtD
Amoxapine—Stomatitis—Cisplatin—esophageal cancer	0.0022	0.0101	CcSEcCtD
Amoxapine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00214	0.0098	CcSEcCtD
Amoxapine—SLC6A2—lymph node—esophageal cancer	0.00214	0.00894	CbGeAlD
Amoxapine—Urinary retention—Capecitabine—esophageal cancer	0.00206	0.0094	CcSEcCtD
Amoxapine—CYP2D6—digestive system—esophageal cancer	0.00205	0.00857	CbGeAlD
Amoxapine—Ataxia—Capecitabine—esophageal cancer	0.00203	0.00929	CcSEcCtD
Amoxapine—Gynaecomastia—Methotrexate—esophageal cancer	0.00198	0.00907	CcSEcCtD
Amoxapine—Tinnitus—Cisplatin—esophageal cancer	0.00189	0.00865	CcSEcCtD
Amoxapine—HTR2A—lung—esophageal cancer	0.00188	0.00786	CbGeAlD
Amoxapine—Alopecia—Cisplatin—esophageal cancer	0.00179	0.00819	CcSEcCtD
Amoxapine—Clozapine—CYP1B1—esophageal cancer	0.00175	0.186	CrCbGaD
Amoxapine—Flatulence—Cisplatin—esophageal cancer	0.00174	0.00795	CcSEcCtD
Amoxapine—Weight increased—Capecitabine—esophageal cancer	0.0017	0.00777	CcSEcCtD
Amoxapine—Vision blurred—Cisplatin—esophageal cancer	0.00166	0.00761	CcSEcCtD
Amoxapine—Tremor—Cisplatin—esophageal cancer	0.00165	0.00756	CcSEcCtD
Amoxapine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00164	0.00751	CcSEcCtD
Amoxapine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00164	0.00751	CcSEcCtD
Amoxapine—Myocardial infarction—Capecitabine—esophageal cancer	0.00163	0.00746	CcSEcCtD
Amoxapine—Jaundice—Capecitabine—esophageal cancer	0.00162	0.00742	CcSEcCtD
Amoxapine—Stomatitis—Capecitabine—esophageal cancer	0.00162	0.00742	CcSEcCtD
Amoxapine—Leukopenia—Cisplatin—esophageal cancer	0.00158	0.00723	CcSEcCtD
Amoxapine—Agranulocytosis—Capecitabine—esophageal cancer	0.00155	0.00711	CcSEcCtD
Amoxapine—HRH1—lymph node—esophageal cancer	0.00154	0.00644	CbGeAlD
Amoxapine—Convulsion—Cisplatin—esophageal cancer	0.00153	0.00699	CcSEcCtD
Amoxapine—Ataxia—Methotrexate—esophageal cancer	0.00151	0.00692	CcSEcCtD
Amoxapine—ADRA2A—lymph node—esophageal cancer	0.00151	0.00632	CbGeAlD
Amoxapine—Hepatitis—Capecitabine—esophageal cancer	0.0015	0.00684	CcSEcCtD
Amoxapine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00149	0.0068	CcSEcCtD
Amoxapine—Oedema—Cisplatin—esophageal cancer	0.00144	0.00659	CcSEcCtD
Amoxapine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00141	0.00645	CcSEcCtD
Amoxapine—Tachycardia—Cisplatin—esophageal cancer	0.00141	0.00643	CcSEcCtD
Amoxapine—Tinnitus—Capecitabine—esophageal cancer	0.00139	0.00637	CcSEcCtD
Amoxapine—Eosinophilia—Methotrexate—esophageal cancer	0.00138	0.00629	CcSEcCtD
Amoxapine—Anorexia—Cisplatin—esophageal cancer	0.00137	0.00628	CcSEcCtD
Amoxapine—Pancreatitis—Methotrexate—esophageal cancer	0.00136	0.00623	CcSEcCtD
Amoxapine—Clozapine—CYP2A6—esophageal cancer	0.00135	0.144	CrCbGaD
Amoxapine—Hypotension—Cisplatin—esophageal cancer	0.00135	0.00616	CcSEcCtD
Amoxapine—Alopecia—Capecitabine—esophageal cancer	0.00132	0.00604	CcSEcCtD
Amoxapine—Paraesthesia—Cisplatin—esophageal cancer	0.00129	0.00592	CcSEcCtD
Amoxapine—Flatulence—Capecitabine—esophageal cancer	0.00128	0.00586	CcSEcCtD
Amoxapine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00128	0.00585	CcSEcCtD
Amoxapine—Dysgeusia—Capecitabine—esophageal cancer	0.00127	0.00583	CcSEcCtD
Amoxapine—Decreased appetite—Cisplatin—esophageal cancer	0.00125	0.00573	CcSEcCtD
Amoxapine—Drowsiness—Methotrexate—esophageal cancer	0.00124	0.00567	CcSEcCtD
Amoxapine—Vision blurred—Capecitabine—esophageal cancer	0.00123	0.00561	CcSEcCtD
Amoxapine—Tremor—Capecitabine—esophageal cancer	0.00122	0.00557	CcSEcCtD
Amoxapine—Stomatitis—Methotrexate—esophageal cancer	0.00121	0.00552	CcSEcCtD
Amoxapine—Feeling abnormal—Cisplatin—esophageal cancer	0.00119	0.00543	CcSEcCtD
Amoxapine—Syncope—Capecitabine—esophageal cancer	0.00117	0.00534	CcSEcCtD
Amoxapine—Leukopenia—Capecitabine—esophageal cancer	0.00117	0.00533	CcSEcCtD
Amoxapine—Agranulocytosis—Methotrexate—esophageal cancer	0.00116	0.00529	CcSEcCtD
Amoxapine—Palpitations—Capecitabine—esophageal cancer	0.00115	0.00526	CcSEcCtD
Amoxapine—Loss of consciousness—Capecitabine—esophageal cancer	0.00114	0.00523	CcSEcCtD
Amoxapine—Body temperature increased—Cisplatin—esophageal cancer	0.00114	0.00521	CcSEcCtD
Amoxapine—Hypertension—Capecitabine—esophageal cancer	0.00112	0.00514	CcSEcCtD
Amoxapine—Hepatitis—Methotrexate—esophageal cancer	0.00111	0.00509	CcSEcCtD
Amoxapine—Dry mouth—Capecitabine—esophageal cancer	0.00108	0.00495	CcSEcCtD
Amoxapine—Confusional state—Capecitabine—esophageal cancer	0.00107	0.0049	CcSEcCtD
Amoxapine—Oedema—Capecitabine—esophageal cancer	0.00106	0.00486	CcSEcCtD
Amoxapine—Shock—Capecitabine—esophageal cancer	0.00105	0.00478	CcSEcCtD
Amoxapine—Diazepam—PTGS1—esophageal cancer	0.00105	0.112	CrCbGaD
Amoxapine—Thrombocytopenia—Capecitabine—esophageal cancer	0.00104	0.00475	CcSEcCtD
Amoxapine—Tinnitus—Methotrexate—esophageal cancer	0.00104	0.00474	CcSEcCtD
Amoxapine—Tachycardia—Capecitabine—esophageal cancer	0.00104	0.00474	CcSEcCtD
Amoxapine—Asthenia—Cisplatin—esophageal cancer	0.00103	0.00473	CcSEcCtD
Amoxapine—Anorexia—Capecitabine—esophageal cancer	0.00101	0.00463	CcSEcCtD
Amoxapine—Hypotension—Capecitabine—esophageal cancer	0.000993	0.00454	CcSEcCtD
Amoxapine—Diarrhoea—Cisplatin—esophageal cancer	0.000986	0.00451	CcSEcCtD
Amoxapine—Alopecia—Methotrexate—esophageal cancer	0.000984	0.0045	CcSEcCtD
Amoxapine—Olanzapine—ABCB1—esophageal cancer	0.000961	0.103	CrCbGaD
Amoxapine—Insomnia—Capecitabine—esophageal cancer	0.000961	0.00439	CcSEcCtD
Amoxapine—Paraesthesia—Capecitabine—esophageal cancer	0.000954	0.00436	CcSEcCtD
Amoxapine—Dysgeusia—Methotrexate—esophageal cancer	0.000949	0.00434	CcSEcCtD
Amoxapine—Dyspepsia—Capecitabine—esophageal cancer	0.000935	0.00427	CcSEcCtD
Amoxapine—Decreased appetite—Capecitabine—esophageal cancer	0.000924	0.00422	CcSEcCtD
Amoxapine—Vomiting—Cisplatin—esophageal cancer	0.000916	0.00419	CcSEcCtD
Amoxapine—Fatigue—Capecitabine—esophageal cancer	0.000916	0.00419	CcSEcCtD
Amoxapine—Vision blurred—Methotrexate—esophageal cancer	0.000913	0.00417	CcSEcCtD
Amoxapine—Rash—Cisplatin—esophageal cancer	0.000909	0.00415	CcSEcCtD
Amoxapine—Constipation—Capecitabine—esophageal cancer	0.000909	0.00415	CcSEcCtD
Amoxapine—Dermatitis—Cisplatin—esophageal cancer	0.000908	0.00415	CcSEcCtD
Amoxapine—Feeling abnormal—Capecitabine—esophageal cancer	0.000876	0.004	CcSEcCtD
Amoxapine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000869	0.00397	CcSEcCtD
Amoxapine—Leukopenia—Methotrexate—esophageal cancer	0.000867	0.00396	CcSEcCtD
Amoxapine—Nausea—Cisplatin—esophageal cancer	0.000856	0.00391	CcSEcCtD
Amoxapine—Urticaria—Capecitabine—esophageal cancer	0.000844	0.00386	CcSEcCtD
Amoxapine—Body temperature increased—Capecitabine—esophageal cancer	0.00084	0.00384	CcSEcCtD
Amoxapine—Abdominal pain—Capecitabine—esophageal cancer	0.00084	0.00384	CcSEcCtD
Amoxapine—Convulsion—Methotrexate—esophageal cancer	0.00084	0.00384	CcSEcCtD
Amoxapine—Confusional state—Methotrexate—esophageal cancer	0.000798	0.00365	CcSEcCtD
Amoxapine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000774	0.00354	CcSEcCtD
Amoxapine—Asthenia—Capecitabine—esophageal cancer	0.000762	0.00348	CcSEcCtD
Amoxapine—Anorexia—Methotrexate—esophageal cancer	0.000754	0.00345	CcSEcCtD
Amoxapine—Pruritus—Capecitabine—esophageal cancer	0.000752	0.00344	CcSEcCtD
Amoxapine—Hypotension—Methotrexate—esophageal cancer	0.000739	0.00338	CcSEcCtD
Amoxapine—Diarrhoea—Capecitabine—esophageal cancer	0.000727	0.00332	CcSEcCtD
Amoxapine—Insomnia—Methotrexate—esophageal cancer	0.000715	0.00327	CcSEcCtD
Amoxapine—Paraesthesia—Methotrexate—esophageal cancer	0.00071	0.00325	CcSEcCtD
Amoxapine—Somnolence—Methotrexate—esophageal cancer	0.000703	0.00321	CcSEcCtD
Amoxapine—Dizziness—Capecitabine—esophageal cancer	0.000703	0.00321	CcSEcCtD
Amoxapine—Dyspepsia—Methotrexate—esophageal cancer	0.000696	0.00318	CcSEcCtD
Amoxapine—Decreased appetite—Methotrexate—esophageal cancer	0.000688	0.00314	CcSEcCtD
Amoxapine—Fatigue—Methotrexate—esophageal cancer	0.000682	0.00312	CcSEcCtD
Amoxapine—Vomiting—Capecitabine—esophageal cancer	0.000676	0.00309	CcSEcCtD
Amoxapine—Rash—Capecitabine—esophageal cancer	0.00067	0.00306	CcSEcCtD
Amoxapine—Dermatitis—Capecitabine—esophageal cancer	0.000669	0.00306	CcSEcCtD
Amoxapine—Headache—Capecitabine—esophageal cancer	0.000666	0.00304	CcSEcCtD
Amoxapine—Feeling abnormal—Methotrexate—esophageal cancer	0.000652	0.00298	CcSEcCtD
Amoxapine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000647	0.00296	CcSEcCtD
Amoxapine—Nausea—Capecitabine—esophageal cancer	0.000631	0.00288	CcSEcCtD
Amoxapine—Urticaria—Methotrexate—esophageal cancer	0.000628	0.00287	CcSEcCtD
Amoxapine—Abdominal pain—Methotrexate—esophageal cancer	0.000625	0.00286	CcSEcCtD
Amoxapine—Body temperature increased—Methotrexate—esophageal cancer	0.000625	0.00286	CcSEcCtD
Amoxapine—Quetiapine—ABCB1—esophageal cancer	0.000583	0.0622	CrCbGaD
Amoxapine—Asthenia—Methotrexate—esophageal cancer	0.000567	0.00259	CcSEcCtD
Amoxapine—Pruritus—Methotrexate—esophageal cancer	0.00056	0.00256	CcSEcCtD
Amoxapine—Diarrhoea—Methotrexate—esophageal cancer	0.000541	0.00247	CcSEcCtD
Amoxapine—Dizziness—Methotrexate—esophageal cancer	0.000523	0.00239	CcSEcCtD
Amoxapine—Diazepam—ABCB1—esophageal cancer	0.000508	0.0542	CrCbGaD
Amoxapine—Vomiting—Methotrexate—esophageal cancer	0.000503	0.0023	CcSEcCtD
Amoxapine—Clozapine—ABCB1—esophageal cancer	0.000502	0.0535	CrCbGaD
Amoxapine—Rash—Methotrexate—esophageal cancer	0.000499	0.00228	CcSEcCtD
Amoxapine—Dermatitis—Methotrexate—esophageal cancer	0.000498	0.00228	CcSEcCtD
Amoxapine—Headache—Methotrexate—esophageal cancer	0.000495	0.00226	CcSEcCtD
Amoxapine—Nausea—Methotrexate—esophageal cancer	0.00047	0.00215	CcSEcCtD
Amoxapine—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	5.73e-05	0.000108	CbGpPWpGaD
Amoxapine—HTR6—Signaling by GPCR—EGFR—esophageal cancer	5.69e-05	0.000107	CbGpPWpGaD
Amoxapine—HTR7—Signaling by GPCR—EGFR—esophageal cancer	5.68e-05	0.000107	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—EGFR—esophageal cancer	5.65e-05	0.000106	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—SMAD4—esophageal cancer	5.63e-05	0.000106	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	5.63e-05	0.000106	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PTGS1—esophageal cancer	5.61e-05	0.000105	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—ENO1—esophageal cancer	5.61e-05	0.000105	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	5.54e-05	0.000104	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—CREBBP—esophageal cancer	5.54e-05	0.000104	CbGpPWpGaD
Amoxapine—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	5.53e-05	0.000104	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—SMAD4—esophageal cancer	5.53e-05	0.000104	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PSME2—esophageal cancer	5.53e-05	0.000104	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PSME1—esophageal cancer	5.53e-05	0.000104	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	5.51e-05	0.000103	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—NOTCH1—esophageal cancer	5.5e-05	0.000103	CbGpPWpGaD
Amoxapine—DRD4—Signaling by GPCR—EGFR—esophageal cancer	5.44e-05	0.000102	CbGpPWpGaD
Amoxapine—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	5.44e-05	0.000102	CbGpPWpGaD
Amoxapine—HTR7—GPCR downstream signaling—PIK3CA—esophageal cancer	5.43e-05	0.000102	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	5.43e-05	0.000102	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—NOTCH1—esophageal cancer	5.42e-05	0.000102	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	5.33e-05	0.0001	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	5.29e-05	9.93e-05	CbGpPWpGaD
Amoxapine—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	5.28e-05	9.92e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	5.25e-05	9.86e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	5.22e-05	9.8e-05	CbGpPWpGaD
Amoxapine—DRD4—GPCR downstream signaling—PIK3CA—esophageal cancer	5.2e-05	9.77e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	5.19e-05	9.75e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—NOS3—esophageal cancer	5.18e-05	9.74e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—NOS3—esophageal cancer	5.18e-05	9.73e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	5.04e-05	9.47e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—NOS3—esophageal cancer	5.04e-05	9.46e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—KDR—esophageal cancer	5.02e-05	9.43e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	5.01e-05	9.4e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—KDR—esophageal cancer	4.99e-05	9.38e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—CREBBP—esophageal cancer	4.98e-05	9.36e-05	CbGpPWpGaD
Amoxapine—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	4.96e-05	9.32e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—NOS3—esophageal cancer	4.96e-05	9.31e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	4.94e-05	9.27e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling by GPCR—PIK3CA—esophageal cancer	4.93e-05	9.26e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—CREBBP—esophageal cancer	4.92e-05	9.24e-05	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—PIK3CA—esophageal cancer	4.91e-05	9.21e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling by GPCR—EGFR—esophageal cancer	4.9e-05	9.2e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—ERBB2—esophageal cancer	4.85e-05	9.11e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—ERBB2—esophageal cancer	4.84e-05	9.1e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Hemostasis—TP53—esophageal cancer	4.84e-05	9.1e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling by GPCR—EGFR—esophageal cancer	4.83e-05	9.08e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	4.8e-05	9.01e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	4.77e-05	8.96e-05	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—TP53—esophageal cancer	4.75e-05	8.91e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—NOS3—esophageal cancer	4.73e-05	8.89e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	4.73e-05	8.88e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling by GPCR—PIK3CA—esophageal cancer	4.72e-05	8.87e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	4.71e-05	8.85e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	4.7e-05	8.83e-05	CbGpPWpGaD
Amoxapine—DRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	4.68e-05	8.79e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—ERBB2—esophageal cancer	4.64e-05	8.71e-05	CbGpPWpGaD
Amoxapine—DRD3—GPCR downstream signaling—PIK3CA—esophageal cancer	4.62e-05	8.67e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—HIF1A—esophageal cancer	4.61e-05	8.65e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	4.53e-05	8.51e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	4.52e-05	8.5e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	4.51e-05	8.47e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	4.51e-05	8.47e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	4.49e-05	8.42e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—NOS3—esophageal cancer	4.46e-05	8.38e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	4.44e-05	8.34e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	4.43e-05	8.31e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—KDR—esophageal cancer	4.41e-05	8.28e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—NOS3—esophageal cancer	4.4e-05	8.27e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—KDR—esophageal cancer	4.34e-05	8.14e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—KDR—esophageal cancer	4.33e-05	8.13e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—KDR—esophageal cancer	4.31e-05	8.1e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	4.29e-05	8.05e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—CCND1—esophageal cancer	4.28e-05	8.05e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—CCND1—esophageal cancer	4.28e-05	8.04e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	4.26e-05	8.01e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	4.25e-05	7.98e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	4.25e-05	7.97e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	4.21e-05	7.91e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	4.19e-05	7.88e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	4.19e-05	7.87e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—ERBB2—esophageal cancer	4.17e-05	7.84e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—CCND1—esophageal cancer	4.16e-05	7.82e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	4.15e-05	7.8e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	4.14e-05	7.78e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	4.14e-05	7.78e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	4.12e-05	7.75e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—ERBB2—esophageal cancer	4.12e-05	7.74e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—CCND1—esophageal cancer	4.1e-05	7.69e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—HMOX1—esophageal cancer	4.09e-05	7.69e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	4.08e-05	7.67e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	4.08e-05	7.65e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	4.06e-05	7.63e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—CREBBP—esophageal cancer	4.03e-05	7.57e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	4.03e-05	7.56e-05	CbGpPWpGaD
Amoxapine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.03e-05	7.56e-05	CbGpPWpGaD
Amoxapine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	4.01e-05	7.52e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	4e-05	7.51e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	3.96e-05	7.44e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	3.94e-05	7.41e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—EP300—esophageal cancer	3.94e-05	7.41e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—EP300—esophageal cancer	3.94e-05	7.4e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.93e-05	7.38e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—CCND1—esophageal cancer	3.91e-05	7.34e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	3.84e-05	7.21e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—EP300—esophageal cancer	3.83e-05	7.2e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	3.82e-05	7.17e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	3.78e-05	7.11e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—EP300—esophageal cancer	3.77e-05	7.08e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	3.76e-05	7.07e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	3.72e-05	6.98e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	3.7e-05	6.95e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	3.7e-05	6.95e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	3.7e-05	6.94e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—CCND1—esophageal cancer	3.69e-05	6.93e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	3.68e-05	6.92e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	3.66e-05	6.87e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—CCND1—esophageal cancer	3.64e-05	6.83e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	3.64e-05	6.83e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	3.64e-05	6.83e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	3.63e-05	6.82e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	3.63e-05	6.81e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	3.62e-05	6.8e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—NOS3—esophageal cancer	3.61e-05	6.77e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—EP300—esophageal cancer	3.6e-05	6.76e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	3.59e-05	6.74e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	3.57e-05	6.71e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	3.57e-05	6.7e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	3.56e-05	6.69e-05	CbGpPWpGaD
Amoxapine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	3.53e-05	6.64e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	3.52e-05	6.61e-05	CbGpPWpGaD
Amoxapine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.48e-05	6.53e-05	CbGpPWpGaD
Amoxapine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.47e-05	6.52e-05	CbGpPWpGaD
Amoxapine—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.46e-05	6.5e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—MYC—esophageal cancer	3.44e-05	6.45e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—MYC—esophageal cancer	3.43e-05	6.45e-05	CbGpPWpGaD
Amoxapine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.41e-05	6.4e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—EP300—esophageal cancer	3.39e-05	6.38e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—NOS3—esophageal cancer	3.37e-05	6.33e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	3.37e-05	6.33e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—EGFR—esophageal cancer	3.36e-05	6.31e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—EGFR—esophageal cancer	3.36e-05	6.31e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—EP300—esophageal cancer	3.35e-05	6.29e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—MYC—esophageal cancer	3.34e-05	6.27e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	3.32e-05	6.23e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	3.31e-05	6.22e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—NOS3—esophageal cancer	3.31e-05	6.21e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PTGS2—esophageal cancer	3.3e-05	6.2e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—NOS3—esophageal cancer	3.3e-05	6.19e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—MYC—esophageal cancer	3.29e-05	6.17e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—EGFR—esophageal cancer	3.27e-05	6.13e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	3.25e-05	6.1e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—EGFR—esophageal cancer	3.21e-05	6.04e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	3.21e-05	6.03e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	3.17e-05	5.96e-05	CbGpPWpGaD
Amoxapine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.16e-05	5.94e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.16e-05	5.93e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	3.16e-05	5.93e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	3.15e-05	5.92e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	3.15e-05	5.92e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	3.14e-05	5.9e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—MYC—esophageal cancer	3.14e-05	5.89e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	3.1e-05	5.82e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	3.09e-05	5.81e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	3.09e-05	5.81e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	3.08e-05	5.79e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—EGFR—esophageal cancer	3.07e-05	5.76e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	3.07e-05	5.76e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	3.05e-05	5.73e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	3.04e-05	5.7e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	3.02e-05	5.66e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MYC—esophageal cancer	2.96e-05	5.56e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—EP300—esophageal cancer	2.92e-05	5.48e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MYC—esophageal cancer	2.92e-05	5.48e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	2.92e-05	5.48e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	2.91e-05	5.47e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—EP300—esophageal cancer	2.9e-05	5.45e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—EGFR—esophageal cancer	2.89e-05	5.43e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.87e-05	5.4e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—EGFR—esophageal cancer	2.86e-05	5.36e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	2.83e-05	5.32e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—TP53—esophageal cancer	2.82e-05	5.3e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	2.82e-05	5.3e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—TP53—esophageal cancer	2.82e-05	5.29e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	2.79e-05	5.24e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CCND1—esophageal cancer	2.78e-05	5.23e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—EP300—esophageal cancer	2.74e-05	5.15e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—TP53—esophageal cancer	2.74e-05	5.15e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	2.74e-05	5.15e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CCND1—esophageal cancer	2.73e-05	5.13e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CCND1—esophageal cancer	2.73e-05	5.12e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—TP53—esophageal cancer	2.7e-05	5.07e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	2.69e-05	5.06e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	2.68e-05	5.04e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	2.66e-05	5e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	2.65e-05	4.98e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	2.64e-05	4.97e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	2.64e-05	4.95e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.63e-05	4.93e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	2.6e-05	4.87e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TP53—esophageal cancer	2.58e-05	4.84e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—EP300—esophageal cancer	2.56e-05	4.81e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MYC—esophageal cancer	2.54e-05	4.78e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MYC—esophageal cancer	2.53e-05	4.75e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—EP300—esophageal cancer	2.52e-05	4.74e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—EP300—esophageal cancer	2.52e-05	4.73e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	2.51e-05	4.72e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—EP300—esophageal cancer	2.51e-05	4.71e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	2.49e-05	4.68e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	2.49e-05	4.67e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	2.48e-05	4.65e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	2.48e-05	4.65e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	2.47e-05	4.64e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TP53—esophageal cancer	2.43e-05	4.56e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	2.41e-05	4.53e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TP53—esophageal cancer	2.4e-05	4.5e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—NOS3—esophageal cancer	2.35e-05	4.41e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2.29e-05	4.31e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MYC—esophageal cancer	2.23e-05	4.19e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MYC—esophageal cancer	2.2e-05	4.13e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MYC—esophageal cancer	2.19e-05	4.12e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MYC—esophageal cancer	2.19e-05	4.11e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—EGFR—esophageal cancer	2.18e-05	4.1e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	2.16e-05	4.06e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	2.15e-05	4.04e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.15e-05	4.04e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	2.15e-05	4.04e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	2.15e-05	4.03e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—EGFR—esophageal cancer	2.15e-05	4.03e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—EGFR—esophageal cancer	2.14e-05	4.02e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	2.1e-05	3.95e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TP53—esophageal cancer	2.09e-05	3.92e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TP53—esophageal cancer	2.08e-05	3.9e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	2.03e-05	3.81e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	2e-05	3.75e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.96e-05	3.67e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	1.9e-05	3.56e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	1.87e-05	3.5e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	1.86e-05	3.5e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	1.86e-05	3.48e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TP53—esophageal cancer	1.83e-05	3.44e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.83e-05	3.43e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TP53—esophageal cancer	1.8e-05	3.39e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TP53—esophageal cancer	1.8e-05	3.38e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TP53—esophageal cancer	1.8e-05	3.37e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—EP300—esophageal cancer	1.79e-05	3.36e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.77e-05	3.32e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1.7e-05	3.19e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	1.64e-05	3.08e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.32e-05	2.48e-05	CbGpPWpGaD
